Breast Cancer | Specialty

Practical Advice for Toxicity Management in HER2+ MBC

February 19th 2021

Using Genomics to Guide Optimal Treatment Sequencing in HR+ Breast Cancer

February 19th 2021

Christos Vaklavas, MD, discusses the progress that has been made in metastatic HR-positive, HER2-negative breast cancer and potential pathways forward for therapeutic sequencing.

Brain Metastases Therapy in Second-Line HER2+ MBC

February 19th 2021

HR+ MBC: Resistance to CDK4/6 Inhibitors

February 19th 2021

Targeting the PI3K/AKT/mTOR Pathway in HR+ MBC

February 19th 2021

Adjuvant Olaparib Showcases iDFS Improvement in BRCA+, High-Risk Early Breast Cancer

February 17th 2021

February 17, 2021 - An independent data monitoring committee has concluded that the phase 3 OlympiA trial examining olaparib crossed the superiority boundary for its primary end point of invasive disease-free survival in patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer.

Using Oral Therapies to Advance Care in MBC

February 16th 2021

Oral Therapies and Dose Reductions in MBC

February 16th 2021

MBC Therapy: Tesetaxel/Capecitabine

February 16th 2021

Schilsky and Gralow Share Advice for ASCO Leadership and Therapeutic Equity in Cancer

February 15th 2021

Dr. Schilsky highlights key milestones in his career with ASCO, Dr. Gralow speaks to the short- and long-term goals she plans to accomplish in her new role at ASCO, and both speak to their thoughts on the future of cancer care.

Off Our Chests: John Marshall, MD, and Liza Marshall Recount Her TNBC Journey

February 15th 2021

John Marshall, MD, and his wife, Liza, recount the challenging journey of Liza's triple-negative breast cancer (TNBC) diagnosis and how John's career as a gastrointestinal oncologist played into the caregiving process. The interview comes ahead of the release of their book, Off Our Chests, which goes further in depth with their experience.

Tucatinib Approved in Europe for Locally Advanced or Metastatic HER2+ Breast Cancer

February 12th 2021

February 12, 2021 - The European Commission has granted marketing authorization to tucatinib for use in combination with trastuzumab and capecitabine in the treatment of adult patients with HER2-positive, locally advanced or metastatic breast cancer who have previously received at least 2 HER2-targeted regimens

Sequencing Therapy in R/R HER2+ MBC

February 12th 2021

Newly FDA Approved Therapies: R/R HER2+ MBC

February 12th 2021

Treating HR+ MBC After Frontline CDK4/6 Therapy

February 12th 2021

Treating PIK3CA Mutations in HR+ MBC

February 12th 2021

Metastatic Breast Cancer Therapy: OPE

February 9th 2021

At-Home Administration of Therapies to Treat MBC

February 9th 2021

Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology

February 8th 2021

Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.

Moving Metastatic Therapy to Early Stage Setting

February 5th 2021